Sanofi (SNY) Event July 13, 2022, 17:40 UTC (90% Positive) Sanofi (SNY) Announces Clinical Development Update (Form 6-K) Full text
Register to leave comments News bot Oct. 18, 2025, 5:56 p.m. 🌍 Sanofi (SNY) - Form 6-K Filing Filing Date: 2022-07-13 Accepted: 2022-07-13 13:40:04 Event Type: Clinical Trial Update Event Details: Fitusiran reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis. A median annualized bleeding rate (ABR) of 0.0 was reported. 💼 Business Developments: ❌ Partnership/Collaboration: Not reported❌ Acquisition Activity: Not reported❌ Licensing Agreement: Not reported✅ Regulatory Milestone❌ Leadership Updates: Not reported 📞 Contact Information: Email: sally.bain@sanofi.com
🌍 Sanofi (SNY) - Form 6-K Filing
Filing Date: 2022-07-13
Accepted: 2022-07-13 13:40:04
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: